11. Perk J, De Backer G, Gohlke H, Graham I, Reiner Ž, Verschuren M, et al. European Guidelines on Cardiovascular Disease Prevention in Clinical

63

DAFTAR PUSTAKA

1. World Health Organization. Global status report on noncommunicable diseases 2014. Geneva: World Health Organization; 2014. 2. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis

for

the

Global

Burden

of

Disease

Study 2010.

Lancet.

2012;380(9859):2224–60. 3. World Health Statistics. Causes of death 2008 : data sources and methods. World Health. 2011;2010(September 2010):1–28. 4. Cardiovascular disease risk factors - Hypertension [Internet]. World Heart Federation. [cited 2016 Jan 17]. Available from: http://www.world-heartfederation.org/cardiovascular-health/cardiovascular-disease-riskfactors/hypertension/ 5. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95. 6. D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008 Feb 12;117(6):743–53. 7. Bouhanick B, Barbosa SLS, Marre M. Hypertension and diabetes. Arch Mal Coeur Vaiss. 2000;93(11, S):1429–34. 8. IDF Diabetes ATLAS. 7th ed. Brussels: International Diabetes Federation; 2015. 12-7 p. 9. WHO | Diabetes [Internet]. World Health Organization; [cited 2015 Nov 23]. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/ 10. American Heart Association. Cardiovascular Disease & Diabetes [Internet]. [cited

2015

Nov

23].

Available

from:

http://www.heart.org/HEARTORG/Conditions/Diabetes/WhyDiabetesMatters/ Cardiovascular-Disease-Diabetes_UCM_313865_Article.jsp/#.VlJnCtLhDIV 63

64

11. Perk J, De Backer G, Gohlke H, Graham I, Reiner Ž, Verschuren M, et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2012;33(13):1635–701. 12. Hong YM. Atherosclerotic cardiovascular disease beginning in childhood. Korean Circ J. 2010;40(1):1–9. 13. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson Jr. SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340(1):14–22. 14. Gómez-Marcos MA, Recio-Rodríguez JI, Rodríguez-Sánchez E, PatinoAlonso MC, Magallón-Botaya R, Martínez-Vizcaino V, et al. Carotid IntimaMedia Thickness in Diabetics and Hypertensive Patients. Rev Española Cardiol (English Ed. Elsevier; 2011 Jul 1;64(7):622–5. 15. Alatab S, Fakhrzadeh H, Sharifi F, Mostashfi A, Mirarefin M, Badamchizadeh Z, et al. Impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes. J Diabetes Metab Disord. 2014;13(1):24. 16. Marieb EN, Hoehn K. Human Anatomy & Physiology. 7th ed. San Francisco: Benjamin Cummings; 2006. 17. Mescher AL. Junqueiras’s Basic Histology: Text and Atlas. 13th ed. New York: McGraw-Hill Education; 2013. 217-24 p. 18. Kumar V, Abbas AK, Aster JC. Robbins Basic Pathology. 9th ed. Philadelphia: Elsevier Saunders; 2013. 335-43 p. 19. Libby P. The Pathogenesis, Prevention, and Treatment of Atherosclerosis. In: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J, editors. Harrison’s Principles of Internal Medicine. 19th ed. McGraw-Hill Education; 2015. p. 291e1–10. 20. Steinl DC, Kaufmann BA. Ultrasound imaging for risk assessment in atherosclerosis. Int J Mol Sci. Multidisciplinary Digital Publishing Institute;

65

2015 Jan 29;16(5):9749–69. 21. Sherwood L. Fisiologi Manusia: dari Sel ke Sistem. 6th ed. Jakarta: Penerbit Buku Kedokteran EGC; 2012. 22. Finn A V, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol. 2010 Jul 1;30(7):1282–92. 23. Antman EM, Loscalzo J. Ischemic Heart Disease. In: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J, editors. Harrison’s Principles of Internal Medicine. 19th ed. McGraw-Hill Education; 2015. p. 1578–92. 24. Coronary Artery Disease [Internet]. National Library of Medicine; [cited 2016 Jan

9].

Available

from:

https://www.nlm.nih.gov/medlineplus/coronaryarterydisease.html 25. Coronary Artery Disease - Coronary Heart Disease [Internet]. [cited 2016 Jan 9].

Available

from:

http://www.heart.org/HEARTORG/Conditions/More/MyHeartandStrokeNews/ Coronary-Artery-Disease---Coronary-HeartDisease_UCM_436416_Article.jsp#.VpENI7aLTIU 26. Antono D, Hamonangani R. Penyakit Arteri Perifer. In: Setiati S, Idrus A, Sudoyo A w, Simadibrata K. M, Setiyohadi B, Syam AF, editors. Buku Ajar Ilmu Penyakit Dalam. 6th ed. Jakarta: InternaPublishing; 2014. p. 1518–28. 27. Ropper AH, Samuels MA. Cerebrovascular Disease. In: Adams and Victor’s Principle of Neurology. 9th ed. New York: McGraw-Hill; 2009. p. 746. 28. Ischemic Stroke | Internet Stroke Center [Internet]. [cited 2016 Jan 17]. Available from: http://www.strokecenter.org/patients/about-stroke/ischemicstroke/ 29. History of the Framingham Heart Study [Internet]. [cited 2016 Jan 8]. Available from: https://www.framinghamheartstudy.org/about-fhs/history.php 30. Hackam DG, Anand SS. Emerging Risk Factors for Atherosclerotic Vascular Disease: A Critical Review of the Evidenc. JAMA. 2003;290(7):932–40. 31. Strom JB, Libby P. Atherosclerosis. In: Lily L, editor. Pathophysiology of Heart Disease. 5th ed. Walter Kluwer; 2011. p. 113–4.

66

32. Adi PR. Pencegahan dan Penatalaksanaan Aterosklerosis. In: Setiati S, Alwi I, Sudoyo AW, Setiyohadi B, Sumandibrata K M, Syam AF, editors. Buku Ajar Ilmu Penyakit Dalam. 6th ed. Jakarta: InternaPublishing; 2014. p. 1427–37. 33. Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Luther T, Hunninghake DB, et al. Implications of Recent Clinical Trials for the Natinal Cholesterol Education Program Adult Treatment Panel III Guidelines. Arterioscler Thromb Vasc Biol. 2004;24:e149–61. 34. European Society of Hypertension - European Society of Cardiology Guidelines Committee. European Society of Hypertension - European Society of Cardiology Guidelines for The Management of Arterial Hypertension. J Hypertens. 2003;21(1011):53. 35. Chobanian A V., Bakris GL, Black HR, Cushman WC, Green L a., Izzo JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation,

and

Treatment

of

High

Blood

Pressure.

Hypertension.

2003;42(6):1206–52. 36. Kementrian Kesehatan RI. Infodatin Hipertensi. Jakarta; 2014. 37. Tedjasukmana P. Tata Laksana Hipertensi. Cdk-192. 2012;39(4):251–5. 38. Alexander RW. Hypertension and the Pathogenesis of Atherosclerosis : Oxidative Stress and the Mediation of Arterial Inflammatory Response: A New Perspective. Hypertension. Lippincott Williams & Wilkins; 1995 Feb 1;25(2):155–61. 39. Purnamasari D. Diagnosis dan klasifikasi diabetes mellitus. In: Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF, editors. Buku Ajar Ilmu Penyakit Dalam. 6th ed. Jakarta: InternaPublishing; 2014. p. 2325–9. 40. Powers AC. Diabetes Mellitus: Complications. In: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J, editors. Harrison’s Principles of Internal Medicine. 19th ed. McGraw-Hill Education; 2015. p. 2422–30. 41. Pedicino D, Giglio AF, Galiffa VA, Trotta F, Liuzzo G. Type 2 Diabetes, Immunity and Cardiovascular Risk: A Complex Relationship. In: Oguntibeju O, editor. Pathophysiology and Complications of Diabetes Mellitus. InTech; 2012.

67

42. Rask-madsen C, King GL. Review Vascular Complications of Diabetes : Mechanisms of Injury and Protective Factors. Cell Metab. Elsevier Inc.; 2012;17(1):20–33. 43. Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in Type 2 Diabetes : Prevalence , Pathophysiology , and Management. Drugs. 2013;73:327–39. 44. Fodor G. Clinical Evidence Handbook: Primary Prevention of CVD: Treating Dyslipidemia. Am Fam Physician. 2011;83(10):1207–8. 45. Adam JMF. Dislipidemia. In: Setiati S, Alwi I, Sudoyo AW, Simadibrata K. M, Setiyohadi B, Syam AF, editors. Buku Ajar Ilmu Penyakit Dalam. 6th ed. Jakarta: InternaPublishing; 2014. p. 2551–60. 46. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486–97. 47. Ballantyne CM, O’Keefe Jr. JH, Gotto Jr. AM. Dyslipidemia & Atherosclerosis Essentials 2009. 4th ed. Jones & Bartlett Publishers; 2009. 48. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. Cardiovascular Diseases. In: How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Centers for Disease Control and Prevention (US); 2010. 49. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26- year follow-up of participants in the Framingham Heart Study. Circulation. 1983 May 1;67(5):968–77. 50. Lovren F, Teoh H, Verma S. Obesity and atherosclerosis: mechanistic insights. Can J Cardiol. 2015 Feb;31(2):177–83. 51. Bowles DK, Laughlin MH. Mechanism of beneficial effects of physical activity on atherosclerosis and coronary heart disease. J Appl Physiol. 2011;111(21):308–10. 52. Gray HH, Dawkins KD, Simpson IA, Morgan JM. Lecture Notes: Kardiologi.

68

5th ed. Wiley; 2008. 53. Vitale C, Miceli M, Rosano GMC. Gender-specific characteristics of atherosclerosis in menopausal women: risk factors, clinical course and strategies for prevention. Climacteric. 2007 Oct;10 Suppl 2:16–20. 54. Nasir K, Michos ED, Rumberger JA, Braunstein JB, Post WS, Budoff MJ, et al. Coronary artery calcification and family history of premature coronary heart disease: sibling history is more strongly associated than parental history. Circulation. 2004 Oct 12;110(15):2150–6. 55. Nasir K, Budoff MJ, Wong ND, Scheuner M, Herrington D, Arnett DK, et al. Family history of premature coronary heart disease and coronary artery calcification: Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2007 Aug 7;116(6):619–26. 56. Michos ED, Vasamreddy CR, Becker DM, Yanek LR, Moy TF, Fishman EK, et al. Women with a low Framingham risk score and a family history of premature coronary heart disease have a high prevalence of subclinical coronary atherosclerosis. Am Hear J. 2005 Dec;150(6):1276–81. 57. Fruchart J-C, Nierman MC, Stroes ESG, Kastelein JJP, Duriez P. New risk factors for atherosclerosis and patient risk assessment. Circulation. 2004 Jun 15;109(23 Suppl 1):III15–9. 58. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation. 1986. p. 1399–406. 59. de Groot E, van Leuven SI, Duivenvoorden R, Meuwese MC, Akdim F, Bots ML, et al. Measurement of carotid intima–media thickness to assess progression and regression of atherosclerosis. Nature. 2008;5(5):280–8. 60. Simova I. Intima-media thickness: Appropriate evaluation and proper measurement, described. E-journal Cardiol Pract. 2015;13. 61. O’Leary DH, Bots ML. Imaging of atherosclerosis: carotid intima-media thickness. Eur Heart J. 2010;31(14):1682–9. 62. Srámek A, Bosch JG, Reiber JH, Van Oostayen JA, Rosendaal FR. Ultrasound assessment of atherosclerotic vessel wall changes: reproducibility of intima-

69

media thickness measurements in carotid and femoral arteries. Invest Radiol. 2000 Dec;35(12):699–706. 63. Touboul P-J, Labreuche J, Vicaut E, Belliard J-P, Cohen S, Kownator S, et al. Country-based reference values and impact of cardiovascular risk factors on carotid intima-media thickness in a French population: the “Paroi Artérielle et Risque

Cardio-Vasculaire”

(PARC)

Study.

Cerebrovasc

Dis.

2009

Jan;27(4):361–7. 64. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use of Carotid Ultrasound to Identify Subclinical Vascular Disease and Evaluate Cardiovascular Disease Risk: A Consensus Statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008;21(2):93–111. 65. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, B??hm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–219. 66. Folkow B. Cardiovascular structural adaptation; its role in the initiation and maintenance of primary hypertension. Clin Sci Mol Med Suppl. 1978;4:3s – 22s. 67. Gaballa MA, Jacob CT, Raya TE, Liu J, Simon B, Goldman S. Large Artery Remodeling

During

Aging :

Biaxial

Passive

and

Active

Stiffness.

Hypertension. 1998 Sep 1;32(3):437–43. 68. Tanaka H, Dinenno FA, Monahan KD, Desouza CA, Seals DR. Carotid artery wall hypertrophy with age is related to local systolic blood pressure in healthy men. Arter Thromb Vasc Biol. 2001;21(1):82–7. 69. Department of Chronic Diseases and Health Promotion. Global Physical Activity Questionnaire. Geneva: World Health Organization; 2012. 1-8 p. 70. Kusumawardani RP. Kontribusi hipertensi terhadap aterosklerosis arteri karotis interna pada pasien pasca stroke iskemik. Universitas Diponegoro;

70

2011. 71. Katakami N, Yamasaki Y, Ayaishi-Okano R, Ohtoshi K, Kaneto H, Matsuhisa M, et al. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia. 2004;47:1906–13. 72. Stettler C, Allemann S, Ju P. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus : Meta-analysis of randomized trials. Am Hear J. 2006;152(1):27–38. 73. Sutton-tyrrell K, Lassila HC, Meilahn E, Bunker C, Matthews KA, Kuller LH. Carotid Atherosclerosis in Premenopausal and Postmenopausal Women and Its Association With Risk Factors Measured After Menopause. Stroke. 1998;29(6):1116–21. 74. Im TS, Chun EJ, Lee MS, Adla T, Kim JA, Choi S Il. Grade-response relationship between blood pressure and severity of coronary atherosclerosis in asymptomatic adults : assessment with coronary CT angiography. Int J Cardiovasc Imaging. 2014;30:105–12. 75. Darmawan A, Tugasworo D, Pemayun TGD. Hiperglikemia dan Aterosklerosis Arteri Karotis Interna pada Penderita Pasca Stroke Iskemik. M Med Indones. 2011;45(1):1–7. 76. Fromm A, Haaland ØA, Naess H, Thomassen L, Waje-andreassen U. Risk factors and their impact on carotid intima-media thickness in young and middle-aged ischemic stroke patients and controls : The Norwegian Stroke in the Young Study. BMC. 2014;7(176):1–8. 77. Johnson ML, Pietz K, Battleman DS, Beyth RJ. Prevalence of Comorbid Hypertension and Dyslipidemia and Associated Cardiovascular Disease. Am J Manag Care. 2004;10(12):926–32. 78. Mihardja L, Soetrisno U, Soegondo S. Prevalence and clinical profile of diabetes mellitus in productive aged urban Indonesians. J Diabetes Investig. 2014;5(5):507–12. 79. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nature. 2009;5(3):150–9.

71

Lampiran 1.

PROSEDUR PENGUKURAN CIMT 1) Memposisikan pemeriksa dan pasien senyaman mungkin dimana pasien terbaring pada tempat tidur dan pemeriksa duduk di samping kanan pasien. 2) Mengekstensikan

leher

dan

memposisikan

kepala

pasien

menoleh

kontralateral terhadap sisi leher yang akan diperiksa, kemudian mengoleskan gel pada leher atau pada transduser. 3) Melakukan skrinning arteri karotis komunis menggunakan transduser dengan orientasi transversal, dari proksimal hingga distal, sambil melihat layar monitor hingga menemukan bulbus karotikus. 4) Memposisikan orientasi transduser menjadi longitudinal pada sisi lateral arteri karotis kemudian merekam pencitraan pada monitor dalam bentuk gambar diam. 5) Melakukan pengukuran CIMT pada dinding jauh pembuluh darah menggunakan perangkat lunak pada alat. 6) Melakukan pemeriksaan dan pengukuran CIMT pada sisi leher yang lain dengan cara yang sama. 7) Mengambil nilai rata – rata CIMT.

72

Lampiran 2. Ethical clearance

73

Lampiran 3. Surat izin melaksanakan penelitian

74

75

Lampiran 4. Informed cosent

76

77

Lampiran 5. Kuesioner

DAFTAR TILIK PENELUSURAN REKAM MEDIK DAN WAWANCARA No. CM

:

Nama

:

Jenis kelamin

:

Umur

:

Pekerjaan

:

Alamat

:

No. HP

:

Tinggi badan : _____cm

Laki-laki

Perempuan

Berat badan

: _____ kg

Kontrol teratur/tidak :

Ya

Tidak

Status merokok

Ya

Tidak

:

Tekanan darah

Lama hipertensi

BMI

: _____ kg/m2

Obat yang diminum

terakhir

Data Hipertensi

Data DM Status DM

:

Ya

Tidak

Anamnesis 3P + kadar GDS

mg/dl

Anamnesis 3P + kadar GDP

mg/dl

Lainnya (diagnosis dokter, mendapat terapi DM)

78

Kadar gula darah terakhir :

GDP______mg/dl;

GDS______ mg/dl

2PP ______mg/dl Kadar HbA1c

:

Lama DM

:

Obat yang diminum

:

Data dislipidemia Status dislipidemia

:

Ya

Tidak

Kadar kolesterol total : ________ mg/dl

(dislipidemia: ≥240 mg/dl)

Kadar kolesterol LDL : ________ mg/dl


Kadar kolesterol HDL : ________ mg/dl

(dislipidemia: <40 mg/dl)

Kadar trigliserida

: ________ mg/dl


Lama dislipidemia

:

Obat yang diminum

:

Komplikasi/ penyakit lainnya

79

GLOBAL PHYSICAL ACTIVITY QUESTIONNAIRE (GPAQ) Jenis Aktivitas

Contoh Aktivitas

Aktivitas ringan

Duduk, berdiri, mencuci piring, memasak, menyetrika, bermain musik, menonton tv, mengemudikan kendaraan, berjalan perlahan

Aktivitas sedang

Menyapu, mengepel, mencuci mobil, menanam tanaman, memanen tanaman, menimba air, bersepeda pergi pulang beraktivitas,

Aktivitas berat

Membawa barang berat, berkebun (menggali), bersepeda (1622km/jam), bermain sepak bola,

Aerobik low-impact, berkuda, voli, berjalan sedang dan cepat, Olahraga sedang bowling, golf, tenis meja, berenang, bersepeda, jogging, menari, tai chi, yoga, kriket

Olahraga berat

Sepak bola, basket, gym angkat berat, berlari, rugby, tennis, aerobik high-impact, aerobik air, menari ballet, berenang cepat

Aktivitas fisik Kode Pertanyaan

Jawaban

Aktivitas saat belajar / bekerja (Aktivitas termasuk kegiatan belajar, latihan, aktivitas rumah tangga, dll Apakah aktivitas sehari- hari Anda, termasuk 1. Ya P1 aktivitas berat (seperti membawa beban berat, 2. Tidak (langsung ke P4) menggali atau pekerjaan konstruksi lain ) ? Berapa hari dalam seminggu Anda P2 hari melakukan aktivitas berat? Berapa lama dalam sehari biasanya Anda P3 Jam menit melakukan aktivitas berat? Apakah aktivitas sehari-hari Anda termasuk aktivitas sedang yang menyebabkan 1. Ya peningkatan nafas dan denyut nadi, seperti P4 2. Tidak (langsung ke P7) mengangkat beban ringan dan jalan sedang (minimal 10 menit secara kontinyu) ? Berapa hari dalam seminggu Anda P5 hari melakukan aktivitas sedang? Berapa lama dalam sehari biasanya Anda P6 Jam menit melakukan aktivitas sedang ?

80

Perjalanan ke dan dari tempat aktivitas Perjalanan ke tempat aktivtias, berbelanja, beribadah diluar, dll) P7

P8

P9

Apakah Anda berjalan kaki atau bersepeda untuk pergi ke suatu tempat minimal 10 menit kontinyu ? Berapa hari dalam seminggu Anda berjalan kaki atau bersepeda untuk pergi ke suatu tempat?

1. Ya 2. Tidak (langsung ke P10)

Berapa lama dalam sehari biasanya Anda berjalan kaki atau bersepeda untuk pergi ke suatu tempat?

hari

Jam

menit

Aktivitas rekreasi (Olaraga, fitnes, dan rekreasi lainnya)

P10

P11

P12

P13

P14

P15

Apakah Anda melakukan olahraga, fitnes, atau rekreasi yang berat seperti lari, sepak bola atau rekreasi lainnya yang mengakibatkan peningkatan nafas dan denyut nadi secara besar (minimal dalam 10 menit secara kontinyu)? Berapa hari dalam seminggu biasanya anda melakukan olahraga, fitness, atau rekreasi yang tergolong berat? Berapa lama dalam sehari biasanya anda melakukan olahraga, fitness, atau rekreasi yang tergolong berat? Apakah Anda melakukan olahraga, fitness, atau rekreasi yang tergolong sedang seperti berjalan cepat, bersepeda, berenang, voli yang mengakibatkan peningkatan nafas dan denyut nadi (minimal dalam 10 menit secara kontinyu)? Berapa hari dalam seminggu biasanya anda melakukan olahraga, fitnes, atau rekreasi lainnya yang tergolong sedang? Berapa lama dalam sehari biasanya anda melakukan olahraga, fitness, atau rekreasi yang tergolong sedang?

1. Ya 2. Tidak (langsung ke P13)

hari

Jam

menit

1. Ya 2. Tidak (langsung ke P16) hari

Jam

menit

Aktivitas menetap (Sedentary behavior) Aktivitaas yang tidak memerlukan banyak gerak seperti duduk saat bekerja, duduk saat di kendaraan, menonton televisi, atau berbaring, KECUALI tidur P16

Berapa lama Anda duduk atau berbaring dalam sehari?

Jam

menit

81

Lampiran 6. Tabulasi Data Subjek Penelitian

No

Nama

Sex

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

RSN KHSK MZNR SRSP STM DJMN KHST SPD FDLM DYSW JMLN AMRL AGST YSPE SHRT NRHS SRWH JPRY SMTW MSYD BDLS HRT SRRH LDNR BSTM WJST STRN UMRH SDD ANDP IDSYR STRS

L P L P P P P L P P P L L L L L P L L P P P P P L P L P L L P L

Usia BMI (tahun) (kg/m2) 52 55 50 55 58 54 33 59 56 58 51 46 49 32 47 30 46 58 43 59 58 51 51 36 58 48 48 37 59 55 59 45

25.8 25.8 23.8 19.6 22.0 25.7 17.7 25.0 25.0 23.0 27.3 24.3 20.1 22.5 25.4 28.3 20.0 27.3 22.0 25.4 32.9 28.8 28.5 25.5 18.6 18.0 20.6 20.8 25.21 27.68 27.94 24.34

Status obesitas

Tekanan darah terakhir

Lama HT (tahun)

Ya Ya Tidak Tidak Tidak Ya Tidak Ya Ya Tidak Ya Tidak Tidak Tidak Ya Ya Tidak Ya Tidak Ya Ya Ya Ya Ya Tidak Tidak Tidak Tidak Ya Ya Ya Tidak

Hipertensi derajat 1 HT terkontrol Hipertensi derajat 1 HT terkontrol Hipertensi derajat 1 Hipertensi derajat 1 Hipertensi derajat 1 Hipertensi derajat 1 Hipertensi derajat 1 Hipertensi derajat 2 Hipertensi derajat 2 Hipertensi derajat 2 Hipertensi derajat 2 Hipertensi derajat 2 HT terkontrol Hipertensi derajat 1 Hipertensi derajat 1 Hipertensi derajat 2 Hipertensi derajat 1 Hipertensi derajat 1 HT terkontrol HT terkontrol HT terkontrol Hipertensi derajat 2 Hipertensi derajat 1 HT terkontrol Hipertensi derajat 1 HT terkontrol HT terkontrol HT terkontrol Hipertensi derajat 1 Hipertensi derajat 2

2 15 2 5 1 10 4 10 <1 21 <1 9 2 2 <1 <1 17 5 <1 <1 10 1 3 2 13 2 <1 1 2 <1 26 <1

82

No

Status DM

Lama DM (tahun)

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Ya Tidak Tidak Ya Tidak Tidak Tidak Ya Tidak Ya Ya Tidak Tidak Tidak Tidak Ya Ya Tidak Tidak Tidak Ya Ya Ya Tidak Tidak Tidak Ya Ya Ya Ya Ya Ya

1 0 0 5 0 0 0 9 0 7 7 0 0 0 0 17 <1 0 0 0 10 1 3 0 0 0 6 <1 12 3 26 5

Tingkat Status aktivitas dislipidemia fisik Ya Tidak Tidak Ya Ya Ya Ya Ya Tidak Ya Ya Ya Ya Tidak Ya Ya Tidak Ya Ya Tidak Ya Ya Ya Ya Tidak Tidak Ya Tidak Tidak Ya Ya Ya

rendah rendah rendah rendah tinggi rendah rendah rendah rendah rendah rendah rendah sedang rendah tinggi rendah rendah rendah rendah sedang rendah sedang sedang sedang rendah sedang sedang rendah sedang rendah rendah tinggi

CIMT (mm) 2.22 0.67 0.35 0.80 0.57 1.64 0.55 0.76 0.74 1.01 0.51 0.70 0.72 0.84 0.79 0.56 0.59 1.20 0.62 0.35 1.15 0.93 0.65 1.03 0.50 0.77 1.14 0.6 0.7 1.17 0.91 1.43

Penyakit Aterosklerosis

PJK PJK SNH PJK

PJK, SNH PJK

SNH PJK, SNH PJK

PJK, SNH PJK

PJK

83

Lampiran 7. Hasil Analisis Statistik Frequencies Frequency Table Jenis kelamin

Valid

Laki-laki

Frequency 15

Percent 46.9

Valid Percent 46.9

Cumulative Percent 46.9 100.0

Perempuan

17

53.1

53.1

Total

32

100.0

100.0

Usia

Valid

Cumulative Percent 15.6

Frequency 5

Percent 15.6

Valid Percent 15.6

40-49

8

25.0

25.0

40.6

50-59

19

59.4

59.4

100.0

Total

32

100.0

100.0

20-39

Obesitas

Valid

Frequency 17

Percent 53.1

Valid Percent 53.1


Tidak

15

46.9

46.9

100.0

Total

32

100.0

100.0

Ya

DM

Valid

Ya

Frequency 16

Percent 50.0

Valid Percent 50.0

Cumulative Percent 50.0 100.0

Tidak

16

50.0

50.0

Total

32

100.0

100.0

Dislipidemia

Valid

Frequency 22

Percent 68.8

Valid Percent 68.8


Tidak

10

31.3

31.3

100.0

Total

32

100.0

100.0

Ya

Tingkat aktivitas fisik

Valid


Rendah

Frequency 21

Percent 65.6

Valid Percent 65.6

Sedang

8

25.0

25.0

90.6

Tinggi

3

9.4

9.4

100.0

32

100.0

100.0

Total

84

Crosstabs Jenis kelamin * DM Crosstab DM Ya Jenis kelamin

Laki-laki

Tidak

Count

8

15

7.5

7.5

15.0

43.8%

50.0%

46.9%

9

8

17

8.5

8.5

17.0

56.3%

50.0%

53.1%

16

16

32

16.0

16.0

32.0

100.0%

100.0%

100.0%

Expected Count % within DM Perempuan

Count Expected Count % within DM

Total


Total

7

Chi-Square Tests

Pearson Chi-Square Continuity Correction

1

Asymp. Sig. (2-sided) .723

.000

1

1.000

.126

1

.723

Value .125b a

Likelihood Ratio

df

Exact Sig. (2-sided)


1.000

.500

Fisher's Exact Test Linear-by-Linear Association

.122

N of Valid Cases

1

.727

32

a. Computed only for a 2x2 table b. 0 cells (.0%) have expected count less than 5. The minimum expected count is 7. 50.

Usia * DM Crosstab DM Ya Usia

20-39


40-49


50-59


Total


Tidak

Total

2

3

5

2.5

2.5

5.0

12.5%

18.8%

15.6%

3

5

8

4.0

4.0

8.0

18.8%

31.3%

25.0%

11

8

19

9.5

9.5

19.0

68.8%

50.0%

59.4%

16

16

32

16.0

16.0

32.0

100.0%

100.0%

100.0%

85

Chi-Square Tests

2


Likelihood Ratio

1.182

2

.554

Linear-by-Linear Association

.867

1

.352

Value 1.174a

Pearson Chi-Square

N of Valid Cases

df

32

a. 4 cells (66.7%) have expected count less than 5. The minimum expected count is 2.50.

Mann-Whitney Test Ranks DM Usia

N

Mean Rank

Sum of Ranks

Ya

16

17.97

287.50

Tidak

16

15.03

240.50

Total

32 Test Statisticsa Usia

Mann-Whitney U Wilcoxon W Z Asymp. Sig. (2-tailed) Exact Sig. [2*(1-tailed Sig.)]

104.500 240.500 -1.008 .313 .381b

a. Grouping Variable: DM b. Not corrected for ties.

Obesitas * DM Crosstab DM Ya Obesitas

Ya

7

17

8.5

8.5

17.0

62.5%

43.8%

53.1%

6

9

15

7.5

7.5

15.0

37.5%

56.3%

46.9%

16

16

32

16.0

16.0

32.0

100.0%

100.0%

100.0%

% within DM Count Expected Count % within DM Total


Total

10

Expected Count Tidak

Tidak

Count

Chi-Square Tests

Pearson Chi-Square Continuity Correction Likelihood Ratio

1


.502

1

.479

1.136

1

.286

Value 1.129b a

df

Fisher's Exact Test Linear-by-Linear Association N of Valid Cases

1.094

1



.479

.240

.296

32


86

Dislipidemia * DM Crosstab DM Ya Dislipidemia

Ya

Tidak

Count

9

22

11.0

11.0

22.0

81.3%

56.3%

68.8%

3

7

10

5.0

5.0

10.0

18.8%

43.8%

31.3%

16

16

32

16.0

16.0

32.0

100.0%

100.0%

100.0%

Expected Count % within DM Tidak


Total


Total

13

Chi-Square Tests

Pearson Chi-Square Continuity Correction

1


1.309

1

.253

2.377

1

.123

Value 2.327b a

Likelihood Ratio

df

Fisher's Exact Test Linear-by-Linear Association

2.255

N of Valid Cases

1



.252

.126

.133

32


Tingkat aktivitas fisik * DM Crosstab DM Ya Tingkat aktivitas fisik

Rendah

Count

21

10.5

10.5

21.0

68.8%

62.5%

65.6%

4

4

8

4.0

4.0

8.0

25.0%

25.0%

25.0%

1

2

3

1.5

1.5

3.0

6.3%

12.5%

9.4%

16

16

32

16.0

16.0

32.0

100.0%

100.0%

100.0%

% within DM Count Expected Count % within DM Tinggi


Total


Total 10

Expected Count Sedang

Tidak 11

Chi-Square Tests

2


Likelihood Ratio

.387

2

.824

Linear-by-Linear Association

.279

1

.597

Pearson Chi-Square

N of Valid Cases

Value .381a

df

32


87

Mann-Whitney Test Ranks DM Tingkat aktivitas fisik

N

Mean Rank

Sum of Ranks

Ya

16

15.88

254.00

Tidak

16

17.13

274.00

Total Test Statistics

32 a

Tingkat aktivitas fisik Mann-Whitney U Wilcoxon W Z Asymp. Sig. (2-tailed) Exact Sig. [2*(1-tailed Sig.)]

118.000 254.000 -.450 .653 b .724


Riwayat merokok*DM Riwayat merokok * DM Crosstabulation DM Ya Riwayat merokok

Ya Tidak

Total

Count % within Riwayat merokok Count % within Riwayat merokok Count % within Riwayat merokok

Tidak

5 38.5% 11 57.9% 16 50.0%

Total

8 61.5% 8 42.1% 16 50.0%

13 100.0% 19 100.0% 32 100.0%

Chi-Square Tests

Value Pearson Chi-Square

df a

1

.280

.518

1

.472

1.174

1

.279

1.166

Continuity Correction

b

Likelihood Ratio

Asymptotic Significance (2-sided)

Exact Sig. (2sided)

Fisher's Exact Test

Exact Sig. (1sided)

.473

Linear-by-Linear Association N of Valid Cases

1.130

1

.236

.288

32

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 6.50. b. Computed only for a 2x2 table

Derajat hipertensi*DM Derajat hipertensi * DM Crosstabulation DM Ya Derajat hipertensi

HT derajat 2

Count

HT derajat 1

% within Derajat hipertensi Count % within Derajat hipertensi

3 37.5% 6 42.9%

Tidak 5 62.5% 8 57.1%

Total 8 100.0% 14 100.0%

88

HT terkontrol

Count % within Derajat hipertensi Count

Total

Pearson Chi-Square Likelihood Ratio N of Valid Cases

% within Derajat hipertensi Chi-Square Tests Asymptotic Significance (2Value Df sided) a 2.386 2 .303 2.438 2 .296 32

7 70.0% 16

3 30.0% 16

10 100.0% 32

50.0%

50.0%

100.0%


Mann-Whitney Test Ranks DM Derajat hipertensi

N

Mean Rank

Sum of Ranks

Ya

16

18.69

299.00

Tidak

16

14.31

229.00

Total

32

Test Statistics

a

Derajat hipertensi Mann-Whitney U Wilcoxon W Z Asymp. Sig. (2-tailed) Exact Sig. [2*(1-tailed Sig.)]

93.000 229.000 -1.413 .158 b .196


Lama hipertensi*DM Lama hipertensi * DM Crosstabulation DM Ya Lama hipertensi

<5 tahun

Count % within Lama hipertensi

5-10 tahun >10 tahun Total

Total

10

11

21

47.6%

52.4%

100.0%

Count % within Lama hipertensi

Tidak

3

3

6

50.0%

50.0%

100.0%

Count

3

2

5

% within Lama hipertensi Count

60.0% 16

40.0% 16

100.0% 32

% within Lama hipertensi

50.0%

50.0%

100.0%

Chi-Square Tests

Value Pearson Chi-Square Likelihood Ratio Linear-by-Linear Association N of Valid Cases

Asymptotic Significance (2sided)

df a

.248 .249 .215

32

2 2 1

.884 a. 4 cells (66.7%) have expected count less than .883 5. The minimum .643 expected count is 2.50.

89

Mann-Whitney Test Ranks DM Lama hipertensi

N

Mean Rank

Sum of Ranks

Ya

16

17.09

273.50

Tidak

16

15.91

254.50

Total

32

Test Statistics

a

Lama hipertensi Mann-Whitney U Wilcoxon W Z Asymp. Sig. (2-tailed) Exact Sig. [2*(1-tailed Sig.)]

118.500 254.500 -.426 .670 b .724


Explore Jenis Kelamin-CIMT (DM - Non DM) Case Summaries CIMT DM

Jenis kelamin

Ya

Laki-laki

N

Perempuan

Mean

Std. Deviation

Median

Minimum

Maximum

7

1.1400

.56654

1.1400

.56

2.22

9

.7944

.21967

.8000

.51

1.15

16

.9456

.43066

.8550

.51

2.22

Tidak

Total Laki-laki

8

.7150

.25219

.7100

.35

1.20

8 16

.7900 .7525

.39587 .32298

.7050 .7100

.35 .35

1.64 1.64

Total

Perempuan Total Laki-laki

15

.9133

.46639

.7600

.35

2.22

Perempuan

17

.7924

.30446

.7400

.35

1.64

Total

32

.8491

.38709

.7500

.35

2.22

Explore Usia-CIMT (DM – Non DM) Case Summaries CIMT DM Ya

Usia 20-39

Tidak

40-49 50-59 Total 20-39

Total

N

Mean

Std. Deviation

Median

Minimum

Maximum

2

.5800

.02828

.5800

.56

.60

3 11 16

1.0533 .9827 .9456

.42665 .45824 .43066

1.1400 .9100 .8550

.59 .51 .51

1.43 2.22 2.22

40-49 50-59 Total 20-39

3 5 8 16 5

.8067 .7200 .7525 .7525 .7160

.24173 .06671 .44975 .32298 .21173

.8400 .7200 .6200 .7100 .6000

.55 .62 .35 .35 .55

1.03 .79 1.64 1.64 1.03

40-49 50-59 Total

8 19 32

.8450 .8858 .8491

.29037 .45712 .38709

.7450 .7600 .7500

.59 .35 .35

1.43 2.22 2.22

90

Explore Obesitas-CIMT (DM) Case Summaries CIMT DM Ya

Tidak

Total

Obesitas Ya

N

Mean

Std. Deviation

Median

Minimum

Maximum

10

.9560

.49858

.8350

.51

2.22

Tidak

6

.9283

.32921

.9050

.59

1.43

Total Ya Tidak Total Ya

16 7 9 16 17

.9456 .9171 .6244 .7525 .9400

.43066 .41744 .15076 .32298 .45339

.8550 .7900 .6200 .7100 .7900

.51 .35 .35 .35 .35

2.22 1.64 .84 1.64 2.22

Tidak

15

.7460

.27466

.7000

.35

1.43

Total

32

.8491

.38709

.7500

.35

2.22

Median

Minimum

Maximum

Explore Dislipidemia-CIMT (DM – Non DM) Case Summaries CIMT DM

Dislipidemia

Ya

Ya

N

Mean

Std. Deviation

13

1.0185

.44784

.9300

.51

2.22

Tidak

3

.6300

.06083

.6000

.59

.70

Total Ya

16

.9456

.43066

.8550

.51

2.22

Tidak

9

.8689

.36057

.7200

.55

1.64

7 16

.6029 .7525

.20246 .32298

.6700 .7100

.35 .35

.84 1.64

Total

Tidak Total Ya

22

.9573

.41207

.8550

.51

2.22

Tidak

10

.6110

.16829

.6350

.35

.84

Total

32

.8491

.38709

.7500

.35

2.22

Explore Tingkat aktivitas fisik-CIMT (DM – Non DM) Case Summaries CIMT DM

Tingkat aktivitas fisik

Ya

Rendah

11

.9345

.48583

.8000

.51

2.22

Sedang

4

.8550

.22576

.8150

.65

1.14

Tinggi

N

Mean

Std. Deviation

Median

Minimum Maximum

1

1.4300

.

1.4300

1.43

1.43

16

.9456

.43066

.8550

.51

2.22

Tidak

Total Rendah

10

.7810

.37734

.6850

.35

1.64

4 2 16

.7175 .6800 .7525

.28016 .15556 .32298

.7450 .6800 .7100

.35 .57 .35

1.03 .79 1.64

Total

Sedang Tinggi Total Rendah

21

.8614

.43389

.7400

.35

2.22

Sedang

8

.7863

.24675

.7450

.35

1.14

Tinggi

3

.9300

.44677

.7900

.57

1.43

Total

32

.8491

.38709

.7500

.35

2.22

91

Explore Riwayat merokok-CIMT (DM-Non DM) Case Summaries CIMT DM

Riwayat merokok

Ya

Ya

N

Minimum

Maximum

5

Mean 1.3040

Std. Deviation .60277

Median 1.1700

.56

2.22

Tidak

11

.7827

.19865

.7600

.51

1.15

Total Ya

16

.9456

.43066

.8550

.51

2.22

Tidak

8

.7150

.25219

.7100

.35

1.20

8 16

.7900 .7525

.39587 .32298

.7050 .7100

.35 .35

1.64 1.64

Total

Tidak Total Ya

13

.9415

.49716

.7900

.35

2.22

Tidak

19

.7858

.28789

.7400

.35

1.64

Total

32

.8491

.38709

.7500

.35

2.22

Explore DM-CIMT Case Summaries CIMT DM Ya

N 16

Mean .9456

Std. Deviation .43066

Median .8550

Minimum .51

Maximum 2.22

Tidak

16

.7525

.32298

.7100

.35

1.64

Total

32

.8491

.38709

.7500

.35

2.22

Tests of Normality Shapiro-Wilk CIMT

DM Ya Tidak

Statistic .828

df

.880

a. Lilliefors Significance Correction

16

Sig. .007

16

.038

92

NPar Tests Mann-Whitney Test

Test Statisticsb

Ranks

CIMT

DM Ya

N 16

Mean Rank 18.78

Sum of Ranks 300.50

Tidak

16

14.22

227.50

Total

32

Mann-Whitney U

CIMT 91.500

Wilcoxon W

227.500

Z

-1.376

Asymp. Sig. (2-tailed)

.169

Exact Sig. [2*(1-tailed Sig.)]

.171

a

a. Not corrected for ties. b. Grouping Variable: DM

Jenis kelamin (Keseluruhan) Explore Tests of Normality a

Kolmogorov-Smirnov CIMT

Jenis kelamin Laki-laki

Statistic

df

.229

Shapiro-Wilk

Sig.

Statistic

df

Sig.

15

.033

.850

15

.017

Perempuan .137 17 *. This is a lower bound of the true significance.

*

.908

17

.092

.200


NPar Tests Mann-Whitney Test Ranks

CIMT

Jenis kelamin Laki-laki

N 15

17.63

264.50

Perempuan Total

17

15.50

263.50

32

Mean Rank

Sum of Ranks

93

Usia (Keseluruhan) Explore Tests of Normality a

Kolmogorov-Smirnov Usia CIMT

Statistic

df

20-39

.308

40-49

.325

50-59

.153

Shapiro-Wilk

Sig. 5

Statistic

df

.136

.834

8

.013

19

.200

*

Sig. 5

.148

.810

8

.036

.872

19

.016

*. This is a lower bound of the true significance. a. Lilliefors Significance Correction

NPar Tests Kruskal-Wallis Test

Obesitas (Keseluruhan) Explore Tests of Normality a

Kolmogorov-Smirnov Obesitas CIMT

Statistic

df

Shapiro-Wilk

Sig.

Statistic

Ya

.166

17

.200

*

Tidak

.166

15

.200

*


df

Sig.

.872

17

.024

.911

15

.141

94

NPar Tests Mann-Whitney Test Ranks Obesitas CIMT

N

Mean Rank

Sum of Ranks

Ya

17

18.65

317.00

Tidak

15

14.07

211.00

Total

32

Dislipidemi (Keseluruhan) Explore Tests of Normality a

Kolmogorov-Smirnov Dislipidemia CIMT

Statistic

df

Sig.

Ya

.149

22

Tidak

.150

10


Shapiro-Wilk Statistic

df

Sig.

.200

*

.865

22

.006

.200

*

.931

10

.454

95

NPar Tests Mann-Whitney Test Ranks Dislipidemia CIMT Ya

Mean Rank

N

Sum of Ranks

22

19.30

424.50

Tidak

10

10.35

103.50

Total

32

Tingkat aktivitas fisik (Keseluruhan) Explore Tests of Normality a

Kolmogorov-Smirnov Tingkat aktivitas fisik CIMT

Statistic

df

Shapiro-Wilk

Sig.

Statistic

df

Sig.

Rendah

.186

21

.055

.826

21

.002

Sedang

.165

8

.200

*

.965

8

.856

Tinggi

.290

3

.

.926

3

.475


96

NPar Tests Kruskal-Wallis Test

Riwayat merokok (Keseluruhan) Explore Tests of Normality a

Kolmogorov-Smirnov Riwayat merokok CIMT

Statistic

df

Shapiro-Wilk

Sig.

Statistic

df

Sig.

Ya

.196

13

.182

.879

13

.069

Tidak

.165

19

.189

.898

19

.045


97

NPar Tests Mann-Whitney Test Ranks Riwayat merokok CIMT

N

Mean Rank

Sum of Ranks

Ya

13

18.00

234.00

Tidak

19

15.47

294.00

Total

32

98

Lampiran 8. Dokumentasi Penelitian

Penjelasan penelitian dan wawancara oleh penulis

Pengambilan data CIMT

99

Lampiran 9. BIODATA MAHASISWA Identitas Nama

: Mutiara Chairsabella

NIM

: 22010112130070

Tempat/Tanggal Lahir: Semarang, 5 September 1994 Jenis Kelamin

: Perempuan

Alamat

: Jl. Wamena Raya D.194/195 Beji, Ungaran

No. Handphone

: 081321347312

Email

: [email protected]

Riwayat Pendidikan Formal 1. SD : SDIT Assalamah Ungaran

Lulus tahun: 2006

2. SMP : SMP Semesta Semarang

Lulus tahun: 2009

3. SMA : SMA Semesta Semarang

Lulus tahun: 2012

4. S1

Masuk tahun: 2012

: Fakultas Kedokteran Universitas Diponegoro

Keanggotaan Organisasi 1. Bidang Hubungan Luar HIMA KU Undip tahun 2013 s/d 2014 2. AMSA Undip tahun 2013 s/d 2014 Publikasi Ilmiah 1. Mutiara Chairsabella, Valensa Yosephi,

Yustina Wahyuningtiyas, Kis

Djamiatun. Vaksin Vektor Virus Penguat BCG Sebagai Upaya Eliminasi Tuberkulosis (TB). JIMKI, 2016, Volume 4, Nomor 1, Halaman 24-34 Prestasi 1. Medali perunggu SIMPIC Faculty of Medicine Mahidol University 2015 2. Medali perunggu II AVSQ AMSW FK Unair 2015

11. Perk J, De Backer G, Gohlke H, Graham I, Reiner Ž, Verschuren M, et al. European Guidelines on Cardiovascular Disease Prevention in Clinical

Recommend Documents